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Abstract
Background
The mean age of acute dengue has undergone a shift towards older ages. This fact points
towards the relevance of assessing the influence of age-related comorbidities, such as dia-
betes, on the clinical presentation of dengue episodes. Identification of factors associated
with a severe presentation is of high relevance, because timely treatment is the most impor-
tant intervention to avert complications and death. This review summarizes and evaluates
the published evidence on the association between diabetes and the risk of a severe clinical
presentation of dengue.
Methodology/Findings
A systematic literature review was conducted using the MEDLINE database to access any
relevant association between dengue and diabetes. Five case-control studies (4 hospital-
based, 1 population-based) compared the prevalence of diabetes (self-reported or abstract-
ed from medical records) of persons with dengue (acute or past; controls) and patients with
severe clinical manifestations. All except one study were conducted before 2009 and all
studies collected information towards WHO 1997 classification system. The reported odds
ratios were formally summarized by random-effects meta-analyses. A diagnosis of diabetes
was associated with an increased risk for a severe clinical presentation of dengue (OR
1.75; 95% CI: 1.08–2.84, p = 0.022).
Conclusions/Significance
Large prospective studies that systematically and objectively obtain relevant signs and
symptoms of dengue fever episodes as well as of hyperglycemia in the past, and at the time
of dengue diagnosis, are needed to properly address the effect of diabetes on the clinical
presentation of an acute dengue fever episode. The currently available epidemiological
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evidence is very limited and only suggestive. The increasing global prevalence of both den-
gue and diabetes justifies further studies. At this point, confirmation of dengue infection as
early as possible in diabetes patients with fever if living in dengue endemic regions seems
justified. The presence of this co-morbidity may warrant closer observation for glycemic
control and adapted fluid management to diminish the risk for a severe clinical presentation
of dengue.
Author Summary
Both dengue and diabetes have reached epidemic dimensions and pose a joint threat to a
large proportion of populations in low- and middle-income countries. Dengue is no longer
a disease primarily affecting children. Therefore the influence of non-communicable dis-
eases such as diabetes, which are increasingly prevalent in adults, on the clinical presenta-
tion of a dengue episode becomes a public health priority. We conducted a systematic
literature review to assess the available evidence on the effect of diabetes mellitus (DM) on
the clinical presentation of dengue. The meta-analysis of published evidence combined
with supporting biological evidence point to an increased risk for potentially life threaten-
ing symptoms of dengue among patients with diabetes. The current evidence is limited by
statistical power and other study limitations and does not allow conclusions about a causal
effect of diabetes. Yet, based on the currently available evidence, diabetes patients with
fever and living in a dengue endemic region should seek confirmation of dengue infection
as early as possible. Diabetes should be considered in the triage of patients for close obser-
vation and early intervention, which are challenges, particularly during dengue outbreaks.
Timeliness of intervention is the most important factor averting serious complications and
death in patients with acute dengue.
Introduction
With low- and middle-income countries (LMIC) experiencing a growing chronic non-commu-
nicable disease (NCD) burden and a continuously high communicable disease (CD) incidence
rate, understanding the co-morbidity between the two disease groups is necessary to properly
assess, monitor, evaluate, and control their prevalence [1,2]. Cardiovascular diseases and their
risk factors including diabetes mellitus (DM) are major contributors to the growing NCD bur-
den [3]. WHO projects that DM will be the 7th leading cause of death in 2030. Today there are
347 million people worldwide who have DM [4], around 90% of them type 2 DM [5]. More
than 80% of DM deaths occur in LMIC[5]. In high income countries DM has long been known
for its association with increased susceptibility to infections such as tuberculosis [6]. Although
these associations have been attributed in part to DM associated alterations in innate immuni-
ty, related evidence is inconsistent and underlying mechanisms remain poorly understood.
They are likely to vary by type of infection [7]. Yet, only few studies investigated the complex
associations of diabetes with neglected tropical diseases (NTDs).
Dengue, one of 17 diseases assigned NTD status by WHO, is next to malaria the most im-
portant arthropo-borne (ARBO) tropical infection caused by the dengue virus. It is transmitted
by several mosquito species within the genus Aedes, principally A. aegypti [8]. The number of
Dengue virus infections has increased 30fold over the last decades. Today it is a major public
health problem in tropical and subtropical regions [9]. The absence of adequate public health
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awareness, surveillance and control, population growth, globalization and urbanization con-
tributed to this increase. An estimated 2.5 billion people are at risk of infection in over 100 en-
demic countries[10]. WHO estimates that currently between 50 and 100 million dengue
infections occur annually. An estimated 500’000 dengue patients with potentially life threaten-
ing symptoms require hospitalization each year and about 2.5% of those affected die [11]. Den-
gue ranges from asymptomatic or self-limiting non-severe dengue (with or without warning
symptoms) to severe dengue, characterized variously by severe plasma leakage, severe bleeding
or severe organ involvement [12]. The studies reviewed in this paper were all except one con-
ducted before 2009 and therefore routine clinical data was collected according to the WHO
1997 guidelines. These guidelines group symptomatic dengue virus infections into three clini-
cal categories: undifferentiated fever, dengue fever (DF), and dengue hemorrhagic fever (DHF).
DHF is further subclassified into four severity grades, with grades III and IV being defined as
dengue shock syndrome (DSS) [13]. The clinical presentation of a dengue infection is difficult
to predict, although the presence of warning signs occurring within 3 to 7 days after the first
symptoms warrant strict observation and medical intervention. Intervention, including intra-
venous rehydration as the therapy of choice, can reduce case fatality in severe dengue to less
than 1% [14]. Dengue has long been viewed as a pediatric disease, but the average age of dengue
cases has been rising and there is a suggestion for adults to be at increased risk for dying from
dengue. The increase of tourism in tropical regions also contributed to the increase in adult
dengue cases [15].
There are five dengue virus (DENV) serotypes (DENV-1, DENV-2, DENV-3, DENV-4 and
DENV-5), however, serotype 5 seems not to have a sustained transmission cycle in humans
[16]. Infection confers immunity to the infecting serotype which is life-long, but not to the re-
maining three. Subsequent infections with a different dengue virus serotype increase the risk of
severe complications [17]. Other than that, factors increasing the risk of severe clinical mani-
festations remain poorly characterized [18–20]. Present evidence suggests that beyond viral
factors age, gender, social status, genetic background, sickle cell anemia, uremia, bronchial
asthma, allergies, hypertension, chronic renal failure and also DMmight adversely influence
the clinical presentation of an infection [18,19,21–24].
In acknowledging the shift of dengue to older ages and the steep increase in the prevalence
of DM, the objective of this review is to access the current clinical and epidemiological evidence
for this NCD to contribute to a higher risk of a severe clinical presentation in dengue fever
patients.
Methods
Search strategy
We conducted a systematic literature review using MEDLINE database to access any relevant
publication describing an association between dengue and diabetes up to February 28 2014.
The search terms used were “("dengue"[MeSH Terms] OR "dengue"[All Fields]) AND ("diabe-
tes mellitus"[MeSH Terms] OR ("diabetes"[All Fields] AND "mellitus"[All Fields]) OR "diabe-
tes mellitus"[All Fields] OR "diabetes"[All Fields]”.
Inclusion criteria
We included articles in all languages; articles which reported on epidemiology, clinical signs,
and laboratory parameters for dengue-infected patients, or on severity assessment. There was
no restriction in publication dates, place of study, study design or age of research participants.
As a validity assessment, the PRISMA criteria were used [25,26].
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For meta-analyses, we included studies that compared the prevalence of DM between per-
sons affected by different dengue stages (case-control studies), reporting estimates of associa-
tion and their 95% confidence intervals, or enough information to derive this.
Data extraction
We extracted the year during which dengue cases were diagnosed (year during which the study
was conducted), year of the publication, country of the study, study design, study definitions of
dengue infection and diabetes, and confounder adjustments. We extracted data on the sample
size of enrolled persons and number of cases and controls and on the estimates (unadjusted
and adjusted models) of the association (and their 95% confidence intervals) between diabetes
and severe dengue. The transition of the patients data from clinical or hospital records to this
review was based on published non-individual and non-identifying data. Data were extracted
from the published papers independently by two reviewers and disagreements were resolved
by discussion.
Case definitions
Dengue. The studies included in this review mostly included dengue diagnosed before
2009 and applied the WHO 1997 dengue classification criteria [13]. A 2009 classification was
proposed by the WHO/TDR group and in 2011 the WHO/SEARO group also suggested modi-
fications [14]. We list the classification system applied in the respective studies in Table 1,
which summarizes the available evidence. Control status and case status are predominantly de-
fined as DF and as DHF or DSS respectively. Cases of DHF/DSS in the studies reviewed were
hospitalized cases or deaths confirmed serologically, clinically with hemorrhagic manifesta-
tions or radiographically with a certain extent of plasma leakage. According to WHO 1997 clas-
sification, DHF is clinically subdivided into grades I-IV and all 4 grades could have some
degree of at least subclinical plasma leakage. Grade I is the presence of fever with positive tour-
niquet test, grade II presents with spontaneous bleeding into the skin and elsewhere, grade III
shows clinical signs of shock or circulatory failure, and grade IV presents with severe shock
with undetectable blood pressure and pulse. Grade III and IV have also been labeled as “dengue
shock syndrome” (DSS). The WHO 2009 classification differs from the 1997 classification
scheme in that dengue cases are classified by the levels of severity with or without warning
signs. Several clinical features specifically listed in the WHO 2009 classification were not direct-
ly obtained in the reviewed studies, e.g. clinical features such as lethargy, restlessness, and se-
vere organ impairment or failure. We refer to DHF/DSS as “severe clinical presentation of
dengue”.
In the reviewed publications, laboratory diagnosis methods to confirm dengue virus infec-
tion as the cause of disease varied across studies and involved detection of virus, viral nucleic
acid, antigens or antibodies, or a combination of these techniques [12]. The detection of virus,
nucleic acid or antigen in the blood is confirmatory for an acute dengue infection. Antibody re-
sponse to infection differs by the host immune status. In the setting of a primary infection, IgM
are the first antibodies to appear, but it takes 10 days for them to be detectable in 99% of pa-
tients. During a secondary dengue infection, anti-dengue IgG are detectable at high levels al-
ready in the acute phase, whereas IgM levels remain significantly lower than in primary dengue
infection. A four-fold or greater increase in IgG antibody levels in paired sera (sample collected
during the acute stage of illness and sample collected in the convalescent stage) indicates acute
dengue [12]. Identification of virus/viral RNA/viral antigen and antibody response are ideally
combined for the confirmation of acute dengue. Yet, as specimen collection and processing is
easier for serology, the laboratory methods applied in the studies mostly conducted in LMIC
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Table 1. Summary of case-control studies and case series.
First author and
publication date
Country & Year of
study
Study design Characteristics of Study population Results(Odds ratios (OR) and 95%
conﬁdence intervals)
Epidemiological case-control studies
Figueiredo et al.
(2010)
Brazil, 2002–2003
(Salvador), 2003–
2005 (Fortaleza)
Population-based
case-control study
Cases:170 acute DHF Predominantly DENV-3,Association DM
—acute DHF vs. asymptomatic (IgG) (+)
ve controls Adjusted OR (age, sex,
income, neighborhood, skin colour,
education)
-registered in the national surveillance
systems
DM yes vs. no.: aOR 2.75 (1.12–6.73)
-residents of 2 cities DM according to the number of
medications: no medication vs. no DM:
aOR 1.83 (0.18–18.67)
-no age restriction 1 medicine vs. no DM: aOR 2.72 (0.86–
8.60)
-diagnostic criteria: Insulin/ >1 medicine vs. no DM:aOR 3.36
(0.72–15.61)
surveillance record review by 2 physicians; DM prevalence: controls:2.6%,
cases:5.3%
Brazilian Health Service (very similar to
WHO 1997) criteria;
fever & positive serology for anti-dengue
IgM and/or viral isolation and
characterization;
at least two signs or symptoms of dengue
fever (headache or retroorbital pain,
myalgia, arthralgia, prostration, exanthema);
all of the following signs: hemorrhagic
manifestations, hemoconcentration with an
increased haematocrit level;
thrombocytopenia;
no consideration of ascites or pleural
effusion (rarely recorded)
Controls: 1175
-neighborhood controls
-sero-positive (anti-dengue IgG)
-self-report of dengue like illness in same
year as matched case
-no history of DHF
-matched for age and sex (within 5 years)
Information on dengue history,
confounders, effect modiﬁers &
comorbidities: in-person interviews with
cases and controls
DM: self-report of physician diagnosis and
veriﬁcation of prescription /packaging of
medication
Mahmood et al
(2013)
Pakistan (2011) Hospital-based
case-control study
Cases: 132 acute DHF Association DM—acute DHF vs.
asymptomatic IgG positive controls:
Adjusted OR (sex, age, duration of
illness)
-admitted to two major tertiary care hospitals
of Lahore
DM yes vs. no: aOR 1.26 (0.78–2.03),
p = 0.34
-age 15–65 DM according to its duration:
(Continued)
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Table 1. (Continued)
First author and
publication date
Country & Year of
study
Study design Characteristics of Study population Results(Odds ratios (OR) and 95%
conﬁdence intervals)
Epidemiological case-control studies
-diagnostic criteria: 5–10 vs. <5 yrs aOR 2.76(0.77–9.84),
p = 0.11
diagnosed as DHF by a trained clinician; >10 vs. <5 yrs:aOR 1.86 (0.55–6.26),
p = 0.31
WHO criteria (version not speciﬁed) DM prevalence: controls: 42%,
cases:43%
Controls: 249 patients without acute
dengue
-random sample of patients from same
health facilities admitted for reasons other
than dengue;
-positive for anti-dengue IgG;
-matched for age and sex (within 5 years);
-Information on dengue history,
confounders, effect modiﬁers & co-
moribities: in-person interviews with cases
and controls; checklist for clinical record
review
DM: self-report or clinical record
Pang et al (2010) Singapore (2006–
2008)
Hospital-based
case-control study
2006 epidemic: Cases:149 acute DHF,
Controls:326 acute DF
2006 epidemic: predominantly DENV-1
2007/2008 epidemic: Cases:590 acute DHF,
Controls:1141 acute DF
27.6% of patients PCR (+)ve
-admitted to the largest hospital of
Singapore for dengue
72.4% of patients sero-positive & PCR(-)
ve
-adult Association DM- acute DHF vs. acuteDF:
Adjusted OR (age, ethnicity)
-diagnostic criteria: DM yes vs. no: aOR 0.34 (0.06–1.89)
probable DF: positive acute dengue
serology (Dengue Duo IgM & IgG Rapid
Strip Test) and clinical criteria of DF by
WHO1997;
DM prevalence: controls: 2.2%, cases:
1.3%
conﬁrmed DF: positive dengue PCR and
clinical criteria of DF by WHO 1997
2007/8 epidemic: predominantly DENV-2
-DHF: presence of all four criteria of fever,
hemorrhagic manifestations,
thrombocytopenia, plasma leakage
32.6% of patients PCR positive
Information on dengue history,
confounders, effect modiﬁers &
comoribities: clinical record review
67.4% of patients sero-positive & PCR (-)
ve
DM: clinical records Association DM- acute DHF vs. acute
DF: aOR (age, ethnicity, gender,
hypertension)
DM yes vs. no: aOR 1.78 (1.06–2.97)
DM with hypertension: aOR 2.16 (1.18–
3.96)
DM with hyperlipidemia:aOR 1.62 (0.90–
2.92)
DM with asthma: aOR 4.38 (0.80–23.85)
DM prevalence: controls:3.5%,
cases:6.4%
(Continued)
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Table 1. (Continued)
First author and
publication date
Country & Year of
study
Study design Characteristics of Study population Results(Odds ratios (OR) and 95%
conﬁdence intervals)
Epidemiological case-control studies
Lee et al. (2006) Taiwan (2002) Hospital-based
case-control study
Cases:232 acute DHF (12 DSS) Association DM- acute DHF/DSS vs.
acute DF: Adjusted OR (factors not
reported)
Controls:412 acute DF DM yes vs. no: aOR 1.86 (1.04–3.37)
-all conﬁrmed acute DF treated at
Kaohshiung Medical University Hospital in
2002
DM prevalence: cases: 16.8%,
controls:7.6%
-no age restriction Plasma leakage prevalence: Pleural
effusion: 51% of DHF cases
-diagnostic criteria for conﬁrmed acute DF: Ascites: 31% of DHF cases
WHO 1997 criteria, meeting any of:
positive dengue virus by PCR;
4-fold increase of dengue virus-speciﬁc IgM
or IgG in paired serum samples;
positive for dengue virus-speciﬁc IgM or IgG
in a single serum sample;
additional diagnostic criteria for conﬁrmed
acute DHF:
Thrombocytopenia;
Evidence for hemorrhage and plasma
leakage;
additional diagnostic criteria DSS:
hypotension, narrow pulse pressure, clinical
signs of shock
Information on dengue history,
confounders, effect modiﬁers &
comoribities: clinical record review
DM: clinical records
Karunakaran
et al (2014)
India (2005–2008) Hospital-based
case-control study
Cases: 10 acute dengue patients, fatal Association DM—mortality among
conﬁrmed acute dengue patients
Controls: 40 acute dengue patients, non-
fatal
DM yes vs. No: Crude OR 26.0 (2.5–
273.7)
-conﬁrmed dengue patients admitted to in
South Kerala hospital between 2005–2008
DM prevalence: controls:2.5%,
cases:40%
diagnostic criteria:
-conﬁrmation by PCR or IgM antibody
Information on dengue history,
symptoms, confounders, effect modiﬁers
& comorbities: semi-structured interview;
assessment of warning signs according to
WHO 2009 case deﬁnition
DM mellitus: self-report
Case series
Lye et al. (2009) Singapore (2004) Hospital-based Cases: 1971 acute DF, DHF, and DSS
cases
DM prevalence: Age <60:2%, Age  60:
17%
-all patients admitted to the Tan Tock Seng
Hospital in Singapore in 2004
- fulﬁlling WHO 1997 criteria for acute
dengue
- positive dengue diagnostic tests:
(Continued)
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Table 1. (Continued)
First author and
publication date
Country & Year of
study
Study design Characteristics of Study population Results(Odds ratios (OR) and 95%
conﬁdence intervals)
Epidemiological case-control studies
- probable dengue:(+)ve acute dengue
serology (Dengue Duo IgM & IgG Rapid
Strip Test)
- conﬁrmed dengue:
- positive PCR
- no age restriction
Information on dengue history,
symptoms, confounders, effect modiﬁers
& comoribities: clinical records
DM: clinical records
Wieten et al.
(2012)
Netherlands (2006–
2011)
Tropical and travel-
medicine based
case series
Cases: 132 acute dengue cases DM prevalence: 8%
-dengue patients serologically tested at
Amsterdam Medical Center between 2006–
2011
-diagnostic criteria:
serological conﬁrmation:positive anti dengue
IgM or at least fourfold increase in dengue
speciﬁc IgG if possible based on one
sample from the initial phase and one from
the convalescent phase or else according to
WHO 2009 criteria for a single sample;
clinical picture of probable dengue (WHO
1997 and 2009 criteria) or DHF (WHO 1997)
or dengue with warning signs (WHO 2009);
Information on dengue history,
symptoms, confounders, effect modiﬁers
& comoribities: clinical records
DM: clinical records
Sam et al (2013) Malaysia (2006–
2007)
Hospital-based Cases: 10 acute DF/DHF/DSS patients,
fatal
DM prevalence: 30% (pre-existing)
-fatal cases at the University Malaya Medical
Center 2006–2007
Plasma leakage prevalence: 78% of all
cases
-diagnostic criteria: (67% among diabetic patients)
laboratory conﬁrmation: acute phase
dengue-speciﬁc IgM and IgG; RT-PCR;
disease severity classiﬁcation WHO 1997;
age range: 11–59;
Information on dengue history,
symptoms, confounders, effect modiﬁers
& comoribities: clinical records
DM: clinical records
Lahiri et al (2008) Singapore (2004–
2005)
Hospital-based Cases: 9 acute dengue cases, fatal DM prevalence: 78%
-fatal cases of a total of 1235 admissions
with acute dengue in 2004–2005
Plasma leakage prevalence: 28% of DM
patients
-all 9 patients had positive laboratory test for
dengue (7 by IgM, 3 by PCR)
-all 9 patients had evidence for capillary
leakage and hemorrhagic manifestations
(Continued)
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varied broadly. We list the laboratory confirmation methods applied in the respective studies
in Table 1, together with the available evidence.
Diabetes mellitus. In studies included in this review, the diagnosis of DM was mostly as-
certained by self-reported diagnosis in the context of in-person interviews or DM diagnosis
listed in clinical records. The DM diagnosis was further verified by requesting the prescription
and/or medication package during the in-person interview in the only population-based case-
control study [27]. An oral glucose tolerance test was performed in dengue patients in the case
series published by Hasanat study [28].
Meta-analysis
We used random-effects models for meta-analyses of the association between DM and a severe
clinical presentation of dengue [29]. They take into consideration the variation between the
true effects estimated by included studies unlike fixed effect models which assume a common
true effect across studies. We used odds ratios as measure of association across all studies. We
used the estimates reported by the authors as “primary model” and the I2 metric and Tau2 to
describe the between study heterogeneity and variance respectively.
We conducted sensitivity analyses by using a fixed effect model and excluding a study,
which was based on non-matched random controls and that only reported unadjusted esti-
mates [30]. We performed analyses with Stata version 12 (Stata Corporation, Texas) and con-
sidered p<0.05 as statistically significant.
Table 1. (Continued)
First author and
publication date
Country & Year of
study
Study design Characteristics of Study population Results(Odds ratios (OR) and 95%
conﬁdence intervals)
Epidemiological case-control studies
-7 of 9 patients strictly met DHF WHO 1997
criteria
- age range: 37–71
Information on dengue history,
symptoms, confounders, effect modiﬁers
& comoribities:
clinical records
DM: clinical records
Hasanat et al.
(2010)
Bangladesh (2009) Hospital-based
(prospective)
Cases: 133 acute dengue cases Status on 1st OGTT (n = 133):
Normal:25%, Glucose intolerant:54%,
DM:21%
-patients admitted to Samoritha Hospital in
Dakha for dengue
Status on 2nd OGTT (n = 40):
- laboratory conﬁrmation by anti-dengue
antibody test 1 week of onset of illness
Normal:83%
-further diagnostic criteria not provided Glucose intolerant:17%
Information on dengue history,
symptoms, confounders, effect modiﬁers
& comorbities: interviews
Repeatedly normal:25%,
DM: Oral glucose tolerance testing in
consenting cases: 1st test between day 3
and 10 of admission and 2nd test before
discharge
Repeatedly abnormal:18%
Reverting to normal:55%
doi:10.1371/journal.pntd.0003741.t001
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Results
Our literature search resulted in 32 hits (Fig 1). After excluding duplicates and non-relevant ar-
ticles based on a full text analysis (single case reports, outbreak investigation reports, no specif-
ic factors studied, narrative overview of dengue infections in a specific country or globally), ten
articles were retained. Among them, five studies were case-control studies [30–33] with one
study being population-based [27]. The case-control studies compared the prevalence of DM
in persons with acute or past non severe dengue (controls) to that in persons with an acute se-
vere clinical presentation of dengue. Five additional articles (case series) characterized DM in
mostly dengue patients with severe clinical manifestations, including fatal cases [28,34–37].
These studies lack a comparison group with acute or past non severe of dengue, and are there-
fore not included in the meta-analysis.
Epidemiological evidence from case-control studies on the association
between DM and a severe clinical presentation of dengue
Epidemiological studies included in the meta-analysis compared the prevalence of DM and
other co-morbidities between patients suffering from acute dengue with a severe presentation
and controls with acute or past dengue without severe clinical manifestations (Table 1). In the
absence of controls without evidence for a dengue infection history, studies thereby compared
the prevalence of DM in dengue patients with different degrees for severity in clinical presenta-
tion, rather than the risk of being infected with dengue virus.
The only population-based case-control study [27] identified was conducted in two Brazil-
ian cities and included both, children and adults. DHF cases were ascertained through the na-
tional surveillance system. The surveillance records were reviewed by two physicians. DHF was
defined according to criteria used by Brazilian Healthy System, which were very close to WHO
1997 criteria. Controls were selected from the same neighborhood as cases. In addition, they
were tested positive for anti-dengue IgG and matched to cases by age, sex and a report of a past
dengue-like fever in the same year as the DHF diagnosis of cases. Additional information from
both, cases and controls was obtained through in-person interviews. DM was based on a self-
reported physician-diagnosis. Interviewers also asked for medication intake and verified it by
seeing the prescription of packaging. DM was statistically significantly associated with DHF in-
dependent of age, sex skin color, income and educational level (aOR 2.75, 95% CI 1.12–6.73).
The association of self-reported diabetes with DHF was stronger in diabetic patients being
treated, especially if treated with insulin or more than 1 drug (aOR 3.36; 95% CI 0.72–15.61).
In addition, white ethnicity (aOR 4.70, 95% CI 2.17–10.2), high income (aOR 6.84, 95% CI
4.09–11.43), high educational level (aOR 4.67, 95% CI 4.09–11.43) and a self-report of allergy
treated with steroids (aOR 2.94, 95% CI 1.01–8.54) were also associated with a more severe
clinical presentation of dengue.
A hospital-based study including persons aged 15 to 65 in Pakistan [31] compared hospital-
ized acute DHF patients (cases) to dengue IgG positive patients, but hospitalized for unrelated
conditions (controls). The study was conducted in two major tertiary care hospitals. A DHF
case was defined as diagnosis by an experienced clinician applying WHO criteria, although the
version applied was not specified. The categorization into persons with and without DHF
points to the use of WHO 1997 criteria. Information was obtained through structured record
review and in-person interview. Age- and sex-matched DHF cases were slightly more likely to
report a DM diagnosis than control patients. In both groups, the reported prevalence of DM
was exceptionally high, 41.8% in controls and 43.2% in cases. The association of DM with DHF
adjusted for age, sex and duration of illness was statistically non-significant (aOR 1.26, 95% CI
0.78–2.03, p = 0.34).
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In Singapore, a hospital-based study was conducted in the nation’s largest clinic. It included
all admitted patients with acute dengue without age restriction [32]. Information on case and
control status as well as comorbidities was exclusively derived from abstracting medical charts.
Cases were defined as DHF patients, and controls were DF patients. Probable dengue patients
Fig 1. PRISMA flow diagram of diabetes and dengue.
doi:10.1371/journal.pntd.0003741.g001
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had a positive acute dengue serology. Confirmed dengue patients had positive dengue polymer-
ase chain reaction assays. Clinical diagnosis for DHF was based on WHO 1997 criteria. The
data was analyzed separately for the two epidemic periods of 2006 (predominantly DENV-1)
and 2007/2008 (predominantly DENV-2; larger sample size). No association between DM sta-
tus and DHF was found in the 2006 dengue outbreak. DM was independently associated with
DHF in the 2007/8 epidemic (aOR 1.78, 95% CI 1.06–2.97). The association was stronger if the
diabetic patients additionally had hypertension (aOR 2.16, 95% CI 1.18–3.96) or asthma (aOR
4.38, 95% CI 0.80–23.85). Mean hospitalization days were longer for DM (4.99±3.34days) as
compared to non-DM patients (4.04±1.62 days, p = 0.001). Additional factors associated with
DHF were Chinese ethnicity (compared to Malay or Indian ethnicity) (aOR 1.90, 95% CI 1.01–
3.56 in 2006 epidemic periods and aOR 1.67, 95% CI 1.24–2.24 in 2007/2008 epidemic periods)
as well as middle age in 2007/2008 (aOR 1.41, 95% CI 1.09–1.81 in 30–39 years and aOR 1.34,
95%CI 1.09–1.81 in 40–49 years of age group).
In 2002 in Taiwan, all patients with confirmed acute DF treated at the Kaoshiung Medical
University Hospital during a large outbreak occurring in the southern Taiwan were categorized
into groups of DF and DHF/DSS by strictly adhering to clinical WHO 1997 criteria and labora-
tory confirmation under the auspices of the Taiwanese Centre of Disease Control [33]. Clinical
information such as signs and symptoms and the results of blood investigation were abstracted
from medical records. Cases were mostly adults, only 4.5% were below age 15 years. The preva-
lence of DM was 16.8% in DHF/DSS cases compared to 7.6% in DF patients (controls). The ad-
justed OR reported was 1.86 (95%CI 1.04–3.37), albeit covariates were not reported. In
addition to the independent association of DHF/DSS with DM, statistically significant associa-
tions with hypertension and renal insufficiency, uremia, past history of dengue infection as
well as male gender and older age were also found.
A hospital-based study in Southern India [30] obtained information on patients admitted to
the largest multi-specialty hospital in South Kerala for acute dengue between 2005 and 2008.
The case group consisted of 10 in-hospital deaths of patients admitted with a clinical diagnosis
of probable dengue, which was confirmed by either RT-PCR or IgM antibody tests, and review
of clinical symptoms through medical record review. Forty non-matched controls were ran-
domly selected among patients with a confirmed acute dengue, but recovering from the illness.
The classification of dengue among the controls was not specified. Information on co-morbidi-
ties and other factors was abstracted from medical records. The prevalence of DM in controls
was 2.5% compared to 40% in cases. DM was a strong predictor of mortality in the bivariate
analysis (OR 26.0, 95% CI 2.47–273.67, p = 0.004). In the same study, hypertension was also a
strong predictor of mortality (OR 44.3, 95% CI 6.2–315.5, p = 0.000). Mortality was much
higher in patients over 40 years (OR 9.3, 95% CI 1.9–44.4, p = 0.002). No adjusted odds ratios,
which would facilitate the interpretation of independency in the reported associations, were
reported.
Meta-analysis of epidemiological evidence from case-control studies
We included the results of five above mentioned studies in a meta-analysis. One of these stud-
ies reported two separate estimates from two independent cross-sectional assessments; hence,
we considered them as separate studies. The meta-analysis showed that the presence of a severe
clinical presentation of dengue was positively associated with the presence of DM.
A diagnosis of DM was associated with an increased risk for severe clinical manifestations
of dengue by 75% (95% CI: 1.08–2.84, p = 0.022) compared to non-DM patients (Fig 2). This
OR remained robust across sensitivity analyses involving fixed effect analysis. We observed
some heterogeneity across the studies, consistent with the broadly differing study settings. The
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small number of studies included in the meta-analysis did not provide statistical power for for-
mal statistical assessment of heterogeneity (Fig 2).
Clinical case series on characteristics of DHF patients
We additionally identified five case series reporting dengue-related hospitalizations and the
prevalence of DM in these cases. They are listed in Table 1 as reference of the prevalence of
DM in dengue patients with a severe clinical presentation. The studies have been conducted
mostly in Asian dengue endemic regions such as Malaysia [36]; Bangladesh [28]; Singapore
[34,35]. In the absence of a control group, these studies are of limited value for better under-
standing of the role of DM on the clinical presentation of dengue. In several instances the case
definition was restricted to just being dengue seropositive. This does not allow differentiating
between DM influencing the clinical manifestations of dengue infection versus dengue infec-
tion influencing the clinical presentation of DM. Of interest, in that respect is the study by
Hasanat et al [28]. Hospitalized DF patients underwent oral glucose tolerance testing (OGTT)
between 3 and 10 days after the start of illness. A subset of these patients agreed to a second
OGTT before discharge. The authors demonstrated a high rate of glucose intolerance in the
early phase of disease, which returned though to normal in 55% of the patients.
Fig 2. Meta-analysis of case-control studies on the association between diabetes mellitus and a severe clinical presentation of dengue.
doi:10.1371/journal.pntd.0003741.g002
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Discussion
The few published studies specifically addressing the role of DM as a risk factor for a severe
clinical presentation of dengue provide suggestive evidence for an adverse effect. This result
merits further investigation in the context of study designs that overcome the weaknesses of
currently available publications as addressed below.
Assigning causality to the modifying effect of diabetes on the clinical presentation of dengue
is premature. First, the case-control studies conducted to date and summarized above are most-
ly retrospective in nature. The clinical and laboratory diagnostic criteria applied in different
studies vary broadly, as does the definition for the control group. Second, the WHO 1997 den-
gue classification used in the studies reviewed, has itself a number of limitations. For example,
the development of this classification was based on disease patterns of children in Thailand,
potentially limiting its generalizability to other geographical regions and to older age groups.
Furthermore, clinical assessments such as the Tourniquet test do not differentiate between DF,
DHF and other febrile illness [38,39]. It also fails to detect severe dengue manifestations in
many patients [40]. Third, information on DM was either self-reported or record-based and
did not systematically allow differentiating between DM diagnosed before versus concurrent
with the dengue episode. Given the high degree of under diagnosis of DM, especially in LMIC,
misclassification of DM status in the studies is likely substantial. The problem of under diagno-
sis is not easy to overcome, as DMmeasured at the time of acute dengue is not necessarily re-
flecting the underlying DM status, but rather stress-related hyperglycemia, which disappears
after recovery from dengue [28]. Longitudinal studies of dengue patients are needed that allow
studying both, the longitudinal course of hyperglycemia and the evolvement of clinical presen-
tation of the dengue infection. In addition, whether better control of DM in early stages of den-
gue will prevent severe forms of dengue needs to be assessed in the context of intervention
studies. The basis should be dengue surveillance programs which registers all dengue episodes
and which includes routine collection of blood specimens for HbA1c and other hyperglycemia
parameters and of information regarding diagnosis and treatment of DM. A fifth limitation of
studies conducted to date is the fact that most of them were hospital-based case-control studies
with a high potential for selection bias. But the results from the only population-based case-
control study also point to DM increasing the risk for a severe clinical presentation of dengue
[27]. Finally, study limitations also include the fact that the modifying effect of DM on different
dengue serotypes could not be differentiated; that the age range of study subjects was not al-
ways reported; and that many studies included children and adolescents in whom DM is rare.
The observed heterogeneity between the results of the individual studies is a limitation in the
meta-analysis and reflects differences in the diagnostic and classification criteria for dengue
and DM, differences in the controls selected, as well as differences in study design such as sam-
ple size, population and study setting or confounders considered in the analysis. Our systemat-
ic and broad search strategy, (not limiting to publication dates, place of study, study design or
age of research participants) and the novelty of this topic are the strengths of our review and
should stimulate further research into the topic, also in the light of supporting results from
experimental studies.
Biological evidence exists to support the hypothesis for a high DHF: DF ratio in diabetes. One
example for a line of reasoning is that the cytokine overload related to a Th1 to Th2 shift and a
severe manifestation of dengue superimposed by the cytokine overload of a diabetic state may be
particularly detrimental to the endothelium and for subsequent vascular leakage [41–43]. The
third space fluid shift such as pleural/pericardial effusion or ascites is an important clinical mani-
festation in dengue with severe clinical symptoms, which is a consequence of endothelial dys-
function and results in hemoconcentration, hypotension and shock [34]. DM shares with a
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severe clinical presentation of dengue alterations in the innate immune response, a pro-inflam-
matory state and endothelial dysfunction. Lee and colleagues infected mononuclear cells from
diabetic (n = 33) and healthy individuals (n = 29) with dengue virus. Cells from diabetics pro-
duced higher levels of IL-4 and of both, IL-4 and IL-10 as well as granulocyte-macrophage colo-
ny-stimulating factor (GM-CSF) on the first and third day post-infection, respectively. No
differences in viral load were found [44]. In a post-mortem study of DHF/DSS related deaths,
the intestinal serosa of 1 DM case with ascites, but not of non-DM cases showed apoptosis of mi-
crovascular endothelial cells [42]. Microvascular endothelial cells cultured with sera from acute
dengue infection patients containing high TNF-α levels exhibited activation and apoptosis, a
pathophysiological alteration likely related to vascular leakage [41].
Currently available epidemiological studies on the DM/DHF, DSS association do not pro-
vide sufficient clinical details to specifically address this “cytokine overload” hypothesis. For ex-
ample, the Brazilian study explicitly stated that it did not look into ascites or pleural effusion,
as these were very rarely recorded [27]. The other studies did not mention plasma leakage such
as pleural effusion or ascites except for the Taiwan study, where 51% of 164 DHF cases showed
evidence of pleural effusion in X- ray and 31% of DHF cases had ascites in ultrasound [33]. Fu-
ture studies thus need to specifically address the issue of plasma leakage in the overlap between
severe dengue and DM. Clinical reporting of the presence of pleural effusion and ascites as
signs of severe plasma leakage is essential, as hemoconcentration and shock symptoms in the
absence of plasma leakage can also arise from poorly controlled DM. The direct hypovolemic
effect of hyperglycemia and the associated elevated hematocrit may even lead to misclassifica-
tion of diabetics as DHF in the absence of objective evidence of plasma leakage. While recogni-
tion of hemoconcentration irrespective of its reason is of primary clinical importance for the
provision of appropriate fluid therapy, currently available studies on the DM and DHF/DSS as-
sociation do not provide sufficient clinical details to differentiate between effects of DM vs.
DHF/DSS.
The potential role of altered innate immunity in mediating the association between DM and
a severe clinical presentation of dengue obtains indirect support by observations that the latter
may also have a higher prevalence of asthma and allergies. Patients with asthma and allergy
also exhibit altered Th1 and Th2 responses [27,31]. But in DM, factors beyond the altered cyto-
kine profile may additionally put people at risk. Diabetic patients express high rates of hyper-
tension and impaired renal function which are both themselves associated with endothelial
dysfunction [45,46]. Hypertension was also observed to be more common in patients with den-
gue [27,30–32,35], but often exhibited no independent effect in regression models adjusting for
diabetes [31,32]. Pang and colleagues (2012) reported a higher risk for a severe clinical presen-
tation of dengue in hypertensive when compared to non-hypertensive diabetic patients [32].
Conclusion
Understanding factors increasing the likelihood of dengue patients with severe clinical symp-
toms would help the physician to decide in a timely fashion on the need for close observation,
adequate treatment, or hospitalization. The available evidence points to DM as a potentially
important co-factor. Additional prospective studies among DM and non-DM patients are
needed to assess the impact of pre-existing DM as well as of hyperglycemia at the time of den-
gue diagnosis on the risk of a severe clinical presentation of dengue and of related deaths. Even
in the absence of causal inference, it seems justified that fever episodes in patients with DM
and living in a dengue endemic region are confirmed for dengue as soon as possible and that
they remain under close surveillance if an acute dengue infection is confirmed. Future studies
need to also address whether better control of glycemia level in dengue patients with DM can
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improve the outcome of the patient and decrease the risk of a severe clinical presentation. As
the fluid management in diabetic patients with a severe clinical presentation of dengue poses a
particular challenge, this issue should be taken into consideration by these studies. Diabetic pa-
tients in dengue endemic regions should consistently receive recommendations to protect
against dengue infection by taking preventive measures against indoor mosquito breeding and
against mosquito bites.
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